Navigation Links
Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
Date:11/15/2007

Unique Collaborative Meeting Includes Leading Scientists Investigating

Pregnancy and Breast Cancer Prevention

HOUSTON, Nov. 15 /PRNewswire/ -- Eighteen scientists investigating novel means for primary prevention of breast cancer by studying the natural impact of pregnancy on breast tissue met at Baylor College of Medicine in Houston on Monday, November 12, 2007 to share interim findings. All are part of the unique Avon Foundation Breast Cancer Prevention Research Initiative, one of many Avon Foundation-funded programs seeking new directions in breast cancer prevention, diagnosis, treatment and cure.

The meeting, convened by the Avon Foundation and Baylor College of Medicine, brought together a network of grant recipients who have been challenged through the Breast Cancer Prevention Research Initiative to use different approaches to address the question: what changes occur in a woman's breast tissue during pregnancy that alter her future risk of breast cancer. The goal is to identify the changes that reduce breast cancer risk and seek ways to provide the protective benefits to all women, regardless of reproductive history.

Pregnancy is associated with profound physiological changes in breast tissue and results in complex, age-dependent effects on breast cancer risk, with a transient increase in risk immediately following pregnancy, followed by long-lasting protection or risk, dependent upon age at first full-term pregnancy. Women who have their first full-term pregnancy before the age of 25 are at a decreased lifetime risk of breast cancer compared to women who never have children or who have a first pregnancy after the age of 35. Although the mechanisms that mediate pregnancy related changes in human breast tissue are poorly understood, it is hoped that a better understanding of these changes might lead to the development of innovative prevention strategies.

While specific interim data will not be released to the public because it is in the early stages, Dr. Marc Hurlbert, Scientific Director of the Avon Foundation, notes that, "we wish to bring the model of this program to the attention of the public and other researchers since collaborations and sharing of interim data is not a typical practice in research. The Avon Foundation hopes to be a change agent in the process of research as well as in the actual studies we fund."

A few of the areas of investigation in the Breast Cancer Prevention Research Initiative include:

-- New techniques to assess physiology and permeability in a woman's

breast under development by Dr. Dixie Mills, Clinical Research

Director, Dr. Susan Love Research Foundation. These techniques move

away from reliance on animal models and biopsy of specimens, and

instead study the physiology of the "living, intact breast."

-- Dr. Christine Erdmann, PhD, MPH, University of Michigan, School of

Public Health, reported her work analyzing epidemiology population data

from prior studies to understand the interactions of critical risk

factors, including age at first pregnancy, body mass index, and alcohol

consumption.

-- Several doctors provided very preliminary reports on their efforts to

understand which genes and proteins change after pregnancy in breast

tissue that could have a later impact on breast cancer.

"These are novel lines of research that will help in the fight to better understand and prevent breast cancer," said Dr. Daniel Medina, Professor, Department of Molecular & Cellular Biology, Baylor College of Medicine. "Baylor is proud to host this collaborative meeting with the Avon Foundation."

"The Breast Cancer Prevention Research Initiative is breaking traditional paradigms," noted Dr. Dixie Mills, "first, by providing funds to support these unusual research studies, and then by fostering collaboration. The Avon Foundation first hosted the grantees in New York in 2006 and now we are together again at Baylor. Twelve months into this multi-year initiative we are sharing data and discussing barriers to success. We will go back to our research after this meeting with fresh ideas and approaches to more rapidly advance our studies."

Attendees include representatives from Baylor College of Medicine, Dana- Farber Cancer Institute, Dr. Susan Love Research Foundation, Fred Hutchinson Cancer Research Center, Johns Hopkins University, Marin County Department of Health, Texas Tech University Health Sciences Center, University of Colorado Health Sciences Center, University of Illinois at Chicago, University of Kansas Medical Center, University of Massachusetts Amherst, University of Michigan, University of Michigan School of Public Health, University of Missouri, University of Nebraska Medical Center, University of Pennsylvania School of Medicine, and University of Wisconsin-Madison.

About the Avon Foundation and the Avon Walk for Breast Cancer Houston

The Avon Foundation is a 501(c)(3) public charity founded in 1955 to improve the lives of women and their families, with a mission now focused on breast cancer and domestic violence. Through 2007 Avon global philanthropy in 50 countries worldwide has raised and awarded more than $580 million, including $525 million raised by the Avon Breast Cancer Crusade to advance access to care and finding a cure. The major fundraising program is the Avon Walk for Breast Cancer series, and the first-ever Avon Walk Houston is slated for April 12-13, 2008. Baylor College of Medicine will be serving as the Medical Sponsor for the inaugural walk year in Houston. For more information: 866-505-AVON or visit http://www.avonfoundation.org.


'/>"/>
SOURCE Avon Foundation; Baylor College of Medicine
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
2. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. The Oral Cancer Foundation Urges HPV Vaccination for Males
6. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
7. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
10. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
11. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):